Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.63 [0.42, 0.94] | | < 1 | | 0% | 1 study (1/-) | 98.9 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.71 [0.49, 1.03] | | < 1 | | 0% | 1 study (1/-) | 96.3 % | NA | not evaluable | | important | - |
objective responses (ORR) | 3.87 [1.55, 9.69] | | > 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.24 [0.01, 5.43] | | < 1 | | 0% | 1 study (1/-) | 81.2 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.36 [0.18, 0.75] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 3.27 [0.63, 16.86] | | < 1 | | 0% | 1 study (1/-) | 7.9 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.63 [0.24, 1.67] | | < 1 | | 0% | 1 study (1/-) | 82.4 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.73 [0.81, 3.73] | | < 1 | | 0% | 1 study (1/-) | 8.0 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 1.02 [0.33, 3.10] | | < 1 | | 0% | 1 study (1/-) | 48.7 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.19 [0.08, 0.46] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.13 [0.05, 0.36] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 1.02 [0.24, 4.26] | | < 1 | | 0% | 1 study (1/-) | 49.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Acute kidney injury TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.25 [0.01, 5.61] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Dermatitis acneiform TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Dyspepsia TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.16 [0.01, 3.32] | | < 1 | | 0% | 1 study (1/-) | 87.8 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.25 [0.01, 5.61] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.09 [0.01, 1.76] | | < 1 | | 0% | 1 study (1/-) | 94.1 % | NA | not evaluable | | non important | - |
Pneumonia TRAE (grade 3-4) | 1.02 [0.06, 16.62] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 1.02 [0.06, 16.62] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |